EXELTIS

Welcome to the Brand page for “EXELTIS”, which is offered here for In the statement, page 1, line 5, pharmaceutical preparation for use in treating should be deleted, and, pharmaceutical preparations for the treatment of ophthalmic diseases and disorders, dermatological diseases and disorders, should be inserted, and, in the statement, page 1, line 8, genitourinary diseases, should be deleted, and, genitourinary disorders, should be inserted, and in the statement, page 1, lines 10 and 11, , neurological diseases, psychiatric diseases, central nervous system should be deleted, and, ; pharmaceutical preparations for the treatment of diseases of the should be inserted, and, in the statement, page 1, line 11, before, respiratory, diseases of the should be inserted, and, in the statement, page 1, line 12, circulatory system should be deleted, and, circulatory diseases should be inserted, and, oral should be deleted, and, mouth should be inserted, and, in the statement, page 1, line 13, headaches, migraine, and hepatic treatments, should be deleted, and, in the statement, page 1, line 14, blood pressure and rheumatic treatments; should be deleted, and, treatment of the liver; should be inserted, and, in the statement, page 1, line 27, after form, ; none of the aforesaid products are preparations in connection with neuroscience, including dementia, alzheimer's disease and parkinson's disease should be inserted, and, in the statement, page 1, lines 28 and 29, ; medical instruments for use in gynecological and respiratory disorders; should be deleted, and, medical instruments for gynecological disorders, ophthalmic disorders, dermatological disorders, metabolic and respiratory disorders; should be inserted, and, in the statement, page 2, line 5, after products, , but none of the aforesaid goods relating to neuroscience, including dementia, alzheimer's disease and parkinson's disease or to goods in the field of neuroscience, including dementia, alzheimer's disease and parkinson's disease should be inserted, and, in the statement, page 2, lines 6 and 7, after, engineering, all the aforesaid goods relating to the field of neuroscience, including dementia, alzheimer's disease and parkinson's disease should be inserted.;[ pharmaceutical preparation for use in treating * ] pharmaceutical preparations for the treatment of [ ophthalmic diseases and disorders, dermatological diseases and disorders, * digestive diseases and disorder, ] gynecological diseases and disorders, hormonal diseases and disorders [, blood disorders, cancer, cardiovascular diseases, vascular diseases, gastrointestinal diseases, genitourinary diseases, * genitourinary disorders, * immunologic diseases, infectious diseases, inflammatory diseases, metabolic diseases and disorders, neurological diseases, psychiatric diseases, central nervous system, * ; pharmaceutical preparations for the treatment of diseases of the * musculoskeletal system, * diseases of the * respiratory system, circulatory system, * circulatory diseases, * viral diseases, glaucoma, dental and oral * mouth * diseases, headaches, migraine, obesity, hepatic treatments, * treatment of the liver; * cholesterol, blood pressure and rheumatic treatments; veterinary preparation for treating digestive diseases and disorder, gynecological diseases and disorders, blood disorders, cancer, cardiovascular diseases, vascular diseases, gastrointestinal diseases, genitourinary diseases, immunologic diseases, infectious diseases, inflammatory diseases, metabolic diseases and disorders, neurological diseases, central nervous system, musculoskeletal system, respiratory system, circulatory system, viral diseases, glaucoma, dental and oral diseases, headaches, migraine, obesity, hepatic treatments, cholesterol, blood pressure and rheumatic treatments; and dietetic foods adapted for medical use, breads, pastas, crackers, chips, snack foods, packaged meals, nutritional food bars, sweets, dips, sauces and food supplements in pill, powder, capsule, beverage form, effervescent tablet and liquid form * ; none of the aforesaid products are preparations in connection with neuroscience, including dementia, alzheimer's disease and parkinson's disease * ];in the statement, page 1, line 40, all should be deleted, and, none, should be inserted.;color is not claimed as a feature of the mark.;[ sales promotion for third parties, business management assistance; consulting on business management and marketing studies; presentation of goods on communication media, for retail purposes; business administration of product licenses and services for others; ] organization of exhibitions, trade fairs or congresses for business or advertising purposes, all relating to pharmaceutical, veterinary and biotechnological companies and for pharmaceutical, veterinary and biotechnological products *, but none of the aforesaid goods relating to neuroscience, including dementia, alzheimer's disease and parkinson's disease or to goods in the field of neuroscience, including dementia, alzheimer's disease and parkinson's disease *;[ surgical apparatus and instruments; [ medical instruments for use in gynecological and respiratory disorders; ] *medical instruments for gynecological disorders, ophthalmic disorders, dermatological disorders, metabolic and respiratory disorders; * orthopedic devices for diagnostic and therapeutic use; suture materials ];[ chemical, biological and pharmaceutical research services; engineering * all * none * the aforesaid goods relating to the field of neuroscience, including dementia, alzheimer's disease and parkinson's disease * ];.

Its status is currently believed to be active. Its class is unavailable. “EXELTIS” is believed to be currently owned by “CHEMO IBERICA, S.A.”